VRCA – verrica pharmaceuticals inc. (US:NASDAQ)
Stock Stats
News
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Verrica Pharmaceuticals (NASDAQ:VRCA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
Verrica Pharmaceuticals (NASDAQ:VRCA) was given a new $17.00 price target on by analysts at Loop Capital.
Form 4 Verrica Pharmaceuticals For: Dec 23 Filed by: Kirby John J.
Form SCHEDULE 13D/A Verrica Pharmaceuticals Filed by: Caligan Partners LP
Form 3 Verrica Pharmaceuticals For: Dec 26 Filed by: Caligan Partners LP
Form 3 Verrica Pharmaceuticals For: Dec 26 Filed by: Frantzreb Charles
Form 8-K Verrica Pharmaceuticals For: Dec 23
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.